inhaled liposomal ciprofloxacin

Inhaled liposomal ciprofloxacin is a formulation of the broad-spectrum fluoroquinolone antibiotic **ciprofloxacin** designed for pulmonary delivery via inhalation. In this formulation, ciprofloxacin is encapsulated in liposomes to allow **sustained release in the lungs**, increase drug residence time, and minimize systemic exposure. This improves tolerability, reduces dosing frequency, and allows for high local concentrations, targeting respiratory pathogens (notably *Pseudomonas aeruginosa*) in diseases such as **cystic fibrosis** and **non-cystic fibrosis bronchiectasis**. The liposomal encapsulation also facilitates ciprofloxacin uptake by phagocytic cells, potentially enhancing treatment of intracellular infections, including nontuberculous mycobacteria. Two main products have been developed: Lipoquin (liposomal ciprofloxacin) and Pulmaquin (dual release, combining free and liposomal ciprofloxacin). The mechanism of action is **inhibition of bacterial topoisomerase II (DNA gyrase) and IV**, thus blocking bacterial DNA replication and transcription[1][3][4].

Brand names

LipoquinPulmaquin

Other names

liposomal ciprofloxacin for inhalationciprofloxacin for inhalationinhaled liposomal ciprofloxacindual release ciprofloxacin for inhalation